{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:36:22Z","timestamp":1787240182581,"version":"build-2736575974"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Nonalcoholic steatohepatitis (NASH) is the progressive stage of nonalcoholic fatty liver disease characterized by varying degrees of inflammation, hepatic steatosis, liver cell damage and fibrosis, which can seriously harm people\u2019s health. Shenling Baizhu (SL) powder exhibits a strong capacity to modulate cellular mechanisms, thereby demonstrating exceptional potential in addressing inflammatory and oxidative stress-related pathologies. However, the exact mechanism of SL in NASH has not been fully elucidated. We aimed to explore the therapeutic effect and potential mechanism of SL in NASH mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We fed mice the methionine-choline deficiency (MCD) diet to construct a model of NASH. The efficacy of SL in regulating the progression of NASH was evaluated by biochemical and histopathological analyses. The effects of SL on oxidative stress and inflammatory cytokines were examined. Transcriptomic analysis was performed to further explore the potential molecular mechanisms regulated by SL. Finally, the expression of key proteins was verified by Western blotting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The pathological phenotype of NASH was successfully established in mice. SL intervention demonstrated significant therapeutic benefits in reducing hepatic lipid accumulation, alleviating liver fibrosis, and decreasing inflammatory responses. Additionally, SL intervention was shown to ameliorate ER stress by attenuating the unfolded protein response (UPR). Gene expression profiling coupled with pathway analysis revealed that SL exerted its effects through the modulation of critical signalling pathways, including the PPAR signalling axis. Additionally, SL inhibited NLRP3 inflammasome activation and reduced the expression of downstream inflammatory cytokines in the liver.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The findings indicate that SL mitigates NASH by activating the PPAR pathway and suppressing the ER stress-triggered UPR, thereby inhibiting NLRP3 inflammasome activation. These results highlight the therapeutic potential of SL for NASH management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1797561","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:04:47Z","timestamp":1787220287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Shenling Baizhu powder alleviates non-alcoholic steatohepatitis by reducing PPAR\u03b1-mediated NLRP3 inflammasome activation"],"prefix":"10.3389","volume":"17","author":[{"given":"Siyuan","family":"Huang","sequence":"first","affiliation":[{"name":"School of Traditional Chinese Medicine, Jinan University, Guangzhou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjun","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, Zhuhai","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajin","family":"Pi","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Jinan University, Guangzhou","place":["Guangdong, China"]},{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou","place":["Guangdong, China"]},{"name":"Postdoctoral Research Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou","place":["Guangdong, China"]},{"name":"The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou","place":["Guangdong, China"]},{"name":"School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyu","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Jinan University, Guangzhou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyue","family":"Pan","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Jinan University, Guangzhou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingliang","family":"Song","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Jinan University, Guangzhou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghao","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Jinan University, Guangzhou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyou","family":"Li","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Jinan University, Guangzhou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhe","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Jinan University, Guangzhou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoxing","family":"Pan","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Jinan University, Guangzhou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupei","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Jinan University, Guangzhou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: A review","volume":"323","author":"Sheka","year":"2020","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1053\/j.gastro.2021.04.074","article-title":"Preparing for the NASH epidemic: A call to action","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103910","article-title":"NAFLD and NASH: etiology, targets and emerging therapies","volume":"29","author":"Wei","year":"2024","journal-title":"Drug Discov Today"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32562","article-title":"Endoplasmic reticulum stress in liver diseases","volume":"77","author":"Ajoolabady","year":"2023","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41467-023-44057-6","article-title":"Mic19 depletion impairs endoplasmic reticulum-mitochondrial contacts and mitochondrial lipid metabolism and triggers liver disease","volume":"15","author":"Dong","year":"2024","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325013","article-title":"NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression","volume":"71","author":"Latif","year":"2022","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1343755","article-title":"Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2019.112105","article-title":"A review of pharmacological and clinical studies on the application of Shenling Baizhu San in treatment of ulcerative colitis","volume":"244","author":"Ma","year":"2019","journal-title":"J Ethnopharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.642685","article-title":"Shenling Baizhu powder inhibits RV-SA11-induced inflammation and rotavirus enteritis via TLR4\/MyD88\/NF-\u03baB signaling pathway","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.883918","article-title":"Shenling Baizhu powder alleviates TNBS-induced colitis in rats by improving intestinal epithelial permeability and inhibiting inflammation through the TLR5\/MyD88\/NF-\u03baB pathway","volume":"13","author":"Rao","year":"2022","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1147067","article-title":"Effects of Shenling Baizhu powder on intestinal microflora metabolites and liver mitochondrial energy metabolism in nonalcoholic fatty liver mice","volume":"14","author":"Yao","year":"2023","journal-title":"Front Microbiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.joim.2021.07.004","article-title":"Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4\/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease","volume":"19","author":"Pan","year":"2021","journal-title":"J Integr Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/4777789","article-title":"The AMPK-mTOR pathway is inhibited by Chaihu Shugan powder, which relieves nonalcoholic steatohepatitis by suppressing autophagic ferroptosis","volume":"2024","author":"Liang","year":"2024","journal-title":"Mediators Inflammation"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155712","article-title":"Shenling Baizhu powder alleviates non-alcoholic fatty liver disease by modulating autophagy and energy metabolism in high-fat diet-induced rats","volume":"130","author":"Pan","year":"2024","journal-title":"Phytomedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121149","article-title":"Netrin-1 attenuates hepatic steatosis via UNC5b\/PPAR\u03b3-mediated suppression of inflammation and ER stress","volume":"311","author":"Choi","year":"2022","journal-title":"Life Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112634","article-title":"Patchouli alcohol alleviates metabolic dysfunction-associated steatohepatitis via inhibiting mitochondria-associated endoplasmic reticulum membrane disruption-induced hepatic steatosis and inflammation in rats","volume":"138","author":"Xie","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/antiox13091026","article-title":"Tanshinone IIA inhibits the endoplasmic reticulum stress-induced unfolded protein response by activating the PPAR\u03b1\/FGF21 axis to ameliorate nonalcoholic steatohepatitis","volume":"13","author":"Pi","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105849","article-title":"Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis","volume":"172","author":"Chen","year":"2021","journal-title":"Pharmacol Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.120282","article-title":"Shenling Baizhu powder and betulin attenuate sepsis-induced intestinal injury by targeting GADD45B\/TAOK1\/p38 MAPK pathway","volume":"353","author":"Xia","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.26599\/FMH.2024.9420002","article-title":"Cornus officinalis vinegar alters the gut microbiota, regulating lipid droplet changes in nonalcoholic fatty liver disease model mice","volume":"1","author":"Cao","year":"2024","journal-title":"Food Med Homology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123723","article-title":"Comprehensive study of the murine MASH models' applicability by comparing human liver transcriptomes","volume":"376","author":"Ning","year":"2025","journal-title":"Life Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.810143","article-title":"Polyene phosphatidylcholine ameliorates high fat diet-induced non-alcoholic fatty liver disease via remodeling metabolism and inflammation","volume":"13","author":"Lu","year":"2022","journal-title":"Front Physiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ar.25333","article-title":"Soybean polyenylphosphatidylcholine (PPC) is beneficial in liver and extrahepatic tissue injury: An update in experimental research","volume":"307","author":"Mak","year":"2024","journal-title":"Anat Rec (Hoboken)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.875700","article-title":"Revealing the mechanism of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156559","article-title":"JiGuCao capsule formula alleviates metabolic fatty liver disease by regulating the gut-liver axis and lipid metabolism","volume":"140","author":"Qi","year":"2025","journal-title":"Phytomedicine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1152\/physrev.00004.2023","article-title":"The liver as a central \"hub\" of the immune system: pathophysiological implications","volume":"105","author":"Ronca","year":"2025","journal-title":"Physiol Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.3390\/ijms23084305","article-title":"PPAR-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients","volume":"23","author":"Lange","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The role of peroxisome proliferator-activated receptors (PPAR) in immune responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"key":"B37","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8969","DOI":"10.3390\/ijms22168969","article-title":"Mechanisms mediating the regulation of peroxisomal fatty acid beta-oxidation by PPAR\u03b1","volume":"22","author":"Tahri-Joutey","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2022.101198","article-title":"Endoplasmic reticulum stress and lipids in health and diseases","volume":"89","author":"Celik","year":"2023","journal-title":"Prog Lipid Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41392-023-01570-w","article-title":"Endoplasmic reticulum stress: molecular mechanism and therapeutic targets","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.042","article-title":"FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease","volume":"75","author":"Liu","year":"2021","journal-title":"J Hepatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE((-\/-)) mice by activating autophagy and reducing ER stress and apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J Hepatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuab016","article-title":"The endoplasmic reticulum unfolded protein response - homeostasis, cell death and evolution in virus infections","volume":"45","author":"Prasad","year":"2021","journal-title":"FEMS Microbiol Rev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2017.05.031","article-title":"The UPR(ER): Sensor and coordinator of organismal homeostasis","volume":"66","author":"Frakes","year":"2017","journal-title":"Mol Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-019-0324-9","article-title":"UPR proteins IRE1 and PERK switch BiP from chaperone to ER stress sensor","volume":"26","author":"Kopp","year":"2019","journal-title":"Nat Struct Mol Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105218","article-title":"Endoplasmic reticulum stress and protein degradation in chronic liver disease","volume":"161","author":"Xia","year":"2020","journal-title":"Pharmacol Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.07.068","article-title":"FXR inhibits endoplasmic reticulum stress-induced NLRP3 inflammasome in hepatocytes and ameliorates liver injury","volume":"24","author":"Han","year":"2018","journal-title":"Cell Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-022-00737-9","article-title":"Sestrin2 protects against cholestatic liver injury by inhibiting endoplasmic reticulum stress and NLRP3 inflammasome-mediated pyroptosis","volume":"54","author":"Han","year":"2022","journal-title":"Exp Mol Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-032521-102529","article-title":"Role of the inflammasome in liver disease","volume":"17","author":"de Carvalho Ribeiro","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrd.2018.149","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14938","article-title":"Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3\/NF-\u03baB pathway in mice","volume":"177","author":"Wang","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154241","article-title":"Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-\u03baB\/NLRP3 signaling pathway","volume":"104","author":"Deng","year":"2022","journal-title":"Phytomedicine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-020-00508-y","article-title":"Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin","volume":"101","author":"Yang","year":"2021","journal-title":"Lab Invest"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1797561\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:04:49Z","timestamp":1787220289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1797561\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2026.1797561"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1797561","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1797561"}}